QIAGEN has been committed to women’s health diagnostics for over 20 years. In this time, QIAGEN has built a comprehensive range of cervical cancer screening solutions to reach as many women as possible. We understand that our customers need different solutions for HPV testing based on their size, setting, and budget.
QIAscreen provides a menu of applications and flexibility in sample input options for HPV testing. Watch the video to find out more about the new QIAscreen test.
The QIAscreen HPV PCR Test is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA of 15 (likely) (1) high-risk HPV genotypes.
QIAscreen can bolster your Rotor-Gene Q workflow, providing a menu of applications on one instrument.
QIAscreen rounds out QIAGEN’s family of PCR-based women’s health tests on the Rotor-Gene Q instrument, which include tests for C. trachomatis, N. gonorrhoeae, and T. vaginalis. Labs can conduct a panel of women’s health tests in a more streamlined and resourceful manner to provide comprehensive insights for clinicians and patients.
1) International Agency for Research on Cancer. (2009). A review of human carcinogens. Part B: Biological Agents. Monographs 100B.
2) Snijders, P.J., Steenbergen, R.D., Heideman, D.A., Meijer, C.J. (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208, 152.
3) QIAscreen HPV PCR Test Instructions for Use. QIAGEN, 2018.
The QIAscreen HPV PCR Test is intended for in vitro diagnostic use in Europe. Self-screen B.V. is the legal manufacturer of the QIAscreen HPV PCR Test.